Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease

This is written in the approval document.

Reimbursement

Hybrid

Atezolizumab - ODMS 2022-03-01; nab-Paclitaxel - Hospital

Citation

Atezolizumab and nab-PACLitaxel Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6530/688_v2a_Atezolizumab_nab-PACLitaxel.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-03-01	Health Service Executive	Indication approved for reimbursement.